PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
Study Details
Study Description
Brief Summary
The goal of this clinical trial is to learn about the efficacy and safety of pablizumab combined with neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.
The main question it aims to answer is: Pathological complete remission (PCR) rate of tumor after neoadjuvant immunotherapy.
Participants will be asked to perform CT and MRI of head and neck, ultrasonography of cervical lymph nodes and necessary laboratory examinations Before and after neoadjuvant therapy. And will be following-up for at least 1 year.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
The secondary questions it aims to answer are:
Objective response rate (ORR) after neoadjuvant therapy
-
R0 resection rate
-
major pathological remission (MPR) rate
-
organ preservation rate
-
event-free survival (EFS)
-
local recurrence-free survival (LRFS)
-
distant metastasis-free survival (DMFS)
-
quality of life score (QoL)
-
overall survival (OS)
-
incidence of adverse events (including neoadjuvant stage AEs and full course AEs) The exploratory question it aims to answer is: clearance of peripheral blood ctDNA.
Study Design
Outcome Measures
Primary Outcome Measures
- Pathological complete remission (pCR) rate of tumor after neoadjuvant immunotherapy. [About 50 days after the start of neoadjuvant immunotherapy.]
pCR means that there are no residual living tumor cells in the tumor bed and lymph nodes after neoadjuvant therapy.
Secondary Outcome Measures
- ORR(objective response rate) [At least 1 year.]
Objective response rates after neoadjuvant immunotherapy were measured, usually as the proportion of patients whose tumor volume decreased by 30% and maintained over 4 weeks, that is, the sum of the rates of complete response (CR) and partial response (PR) , the higher the ORR, the more patients achieved tumor shrinkage with the treatment.
- R0 resection rate [At least 1 year.]
R0 resection is the highest standard of tumor resection, which means complete tumor resection with negative margin. The tumor R0 resection rate was calculated for the patients who underwent surgery after the completion of neoadjuvant immunotherapy.
- MPR（major pathological response） [At least 1 year.]
MPR is defined as the percentage of residual tumor cells in the tumor bed being less than or equal to 10% .
- Overall survival rate [At least 1 year.]
Overall survival is the proportion of all participants who survived the study period. Overall survival was calculated by dividing the number of people alive by the total number at the start of the study.
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [At least 1 year.]
Researchers should grade the severity of each adverse event. If the severity/intensity of an adverse event is not specified in the guidelines, the investigator can assess it based on the general definition of grade 1-5 and in conjunction with his or her medical judgment.
Other Outcome Measures
- clearance of peripheral blood ctDNA [At least 1 year.]
ctDNA is circulating tumor DNA, also known as tumor DNA, which enters the bloodstream when tumor cells die or are released. It is a liquid biopsy method that detects the presence and associated changes of tumor cells in a blood sample.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
age 18-80 years old, including 18 years old and 80 years old;
-
MRI diagnosis of resectable stage III-IVA oropharynx, larynx and hypopharynx squamous-cell carcinoma confirmed by histopathology or cytology;
-
ECOG PS score 0-1;
-
the expression of PD-L1 was detected by immunohistochemistry (TPS and CPS score)
-
having at least one measurable lesion according to RECIST version 1.1;
-
expected survival time ≥6 months;
-
The neutrophil count was ≥1.5 × 109/L, the platelet count was ≥100 × 109/L, the hemoglobin count was ≥90 g/L
-
renal function was normal: serum creatinine ≤1.5×ULN;
-
the liver function was basically normal: serum total bilirubin ≤1.5 × ULN, serum aspartate transaminase (AST)≤2.5×ULN, serum Alanine transaminase (ALT)≤2.5 ×ULN;
-
female patients had to be negative for a urine pregnancy test before the start of the study (not applicable to patients with bilateral oophorectomy and/or hysterectomy or postmenopausal patients) ;
-
Sign the written informed consent.
Exclusion Criteria:
-
patients were treated with anti-tumor drugs including but not limited to PD-1 inhibitor, CTLA-4 antibody, EGFR monoclonal antibody, EGFR-tki, and anti-angiogenesis drugs;
-
History of autoimmune diseases including but not limited to: myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, Rheumatoid Arthritis, inflammatory bowel disease, Antiphospholipid syndrome vascular thrombosis, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis or glomerulonephritis.
-
participated in other intervention clinical trials within 30 days before screening;
-
history of other malignancies (except cured skin basal-cell carcinoma) ;
-
the presence of serious and poorly controlled co-morbidities (e.g. heart failure, diabetes, hypertension, liver failure, kidney failure, thyroid disease, mental illness, etc.) ;
-
Known to be infected with HIV or active hepatitis or tuberculosis;
-
major surgery or planned surgery within 30 days before the first dose of the trial drug;
-
Persons who are allergic to the use of drugs or their components in the programme;
-
pregnancy (confirmed by blood or urine HCG testing) or lactation in women, or in subjects of reproductive age who were unwilling or unable to use effective contraception (for both male and female subjects) until at least 6 months after the last trial treatment;
-
it is not suitable for the researcher to participate in this study;
-
Unwilling to participate in the study or unable to sign the informed consent.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Xijing Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- KY20232325